Relypsa (RLYP) vs. Its Competitors Head-To-Head Contrast
Relypsa (NASDAQ: RLYP) is one of 292 public companies in the “Bio Therapeutic Drugs” industry, but how does it contrast to its rivals? We will compare Relypsa to similar companies based on the strength of its profitability, valuation, institutional ownership, analyst recommendations, risk, dividends and earnings.
Earnings & Valuation
This table compares Relypsa and its rivals top-line revenue, earnings per share and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|Relypsa Competitors||$473.27 million||$171.89 million||-6.94|
Relypsa’s rivals have higher revenue and earnings than Relypsa. Relypsa is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.
Risk & Volatility
Relypsa has a beta of 2.19, indicating that its share price is 119% more volatile than the S&P 500. Comparatively, Relypsa’s rivals have a beta of 6.57, indicating that their average share price is 557% more volatile than the S&P 500.
Institutional & Insider Ownership
51.1% of shares of all “Bio Therapeutic Drugs” companies are owned by institutional investors. 16.9% of shares of all “Bio Therapeutic Drugs” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
This table compares Relypsa and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a summary of current ratings and target prices for Relypsa and its rivals, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
As a group, “Bio Therapeutic Drugs” companies have a potential upside of 32.16%. Given Relypsa’s rivals higher probable upside, analysts plainly believe Relypsa has less favorable growth aspects than its rivals.
Relypsa rivals beat Relypsa on 6 of the 8 factors compared.
Relypsa, Inc. is a United States-based biopharmaceutical company. The Company focuses on the discovery, development and commercialization of polymer-based medicines. The Company’s technology platform includes a high-throughput chemistry process, enabling the Company to explore various potential polymer medicines for each disease it seeks to address. Its polymers are non-absorbed, meaning they act within the gastrointestinal tract and do not get absorbed into the bloodstream or other parts of the body. Its polymer technology may be able to address many health conditions in need of viable treatment options. Its VELTASSA (patiromer) for oral suspension is a commercialized medicine resulting from its polymer technology platform. VELTASSA is a potassium binder approved for the treatment of hyperkalemia. Available in powder form, VELTASSA is mixed with water and taken daily. VELTASSA’s spherical beads bind to potassium in exchange for calcium, primarily in the colon.
Receive News & Ratings for Relypsa Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Relypsa Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.